Q-omics provides the consensus-scored TEX13B profile across patient tissues and cancer cell-line models. TEX13B expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, TEX13B is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, TEX13B RNA expression shows 9,710 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight DLBC, KIRC, and ESCA as cancer lineages where TEX13B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TEX13B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TEX13B survival associations across molecular data types. TEX13B RNA expression shows survival associations in the most cancer types (16), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TEX13B RNA expression–survival associations across cancer types. High TEX13B expression shows unfavorable associations in DLBC, KICH, MESO, CHOL, HNSC and UCEC. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify DLBC as the clearest survival context for TEX13B RNA expression.
This table summarizes TEX13B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TEX13B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TEX13B shows higher tumor expression in KIRC, HNSC, LUSC, BRCA, COAD and LUAD. The KIRC box plot shows higher TEX13B RNA expression in tumor versus normal tissue (log2 FC = +0.028, t-test p = .001).
This table shows molecular features associated with TEX13B in patient tissues and cancer cell lines. In patient samples, TEX13B shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, TEX13B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and UPPER_AERODIGESTIVE_TRACT.
